Precision BioSciences (NASDAQ:DTIL) released its quarterly earnings data on Tuesday. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.15, Fidelity Earnings reports. The company had revenue of $4.87 million during the quarter, compared to the consensus estimate of $5.25 million.
NASDAQ DTIL traded up $0.48 during trading hours on Wednesday, reaching $9.47. 663,300 shares of the company’s stock were exchanged, compared to its average volume of 221,509. Precision BioSciences has a one year low of $6.24 and a one year high of $19.00. The firm has a fifty day moving average of $7.47 and a 200-day moving average of $10.81.
DTIL has been the topic of several analyst reports. BTIG Research initiated coverage on Precision BioSciences in a research note on Friday, August 9th. They issued a “buy” rating and a $22.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Precision BioSciences in a research note on Wednesday. Six analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $22.80.
Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.
Featured Article: What is a recession?
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.